OncoMatch

OncoMatch/Clinical Trials/NCT05230680

Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)

Is NCT05230680 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ACHOP for t cell lymphoma.

Phase 1/2RecruitingWon Seog KimNCT05230680Data as of May 2026

Treatment: ACHOPInduction treatment (every 3 weeks, total 6 cycles) * Azacitidine D-2, -1, 1 (level 1: 50mg/m2, level 2: 75mg/m2, level 3: 100mg/m2, level 4: 125mg/m2) * Cyclophosphamide 750mg/m2 d1 * Doxorubicin 50 mg/m2 d1 * Vincristine 1.4 mg/m2 (Max: 2 mg) d1 * Prednisolone 100mg PO d1-5 Maintenance treatment (every 4 weeks, total 12 cycles) * Azacitidine 75mg/m2 d1-5

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Exception: short-term corticosteroids (for less than 8 days) prior to selection

Previously treated for T-cell lymphoma with immunotherapy or chemotherapy, except for short-term corticosteroids (for less than 8 days) prior to selection

Cannot have received: chemotherapy

History of chemotherapy for Hodgkin's or other non-Hodgkin's lymphoma in the last 5 years

Cannot have received: radiation therapy

Exception: localized to a single lymph node

Prior radiotherapy, except for those localized to a single lymph node

Cannot have received: doxorubicin (doxorubicin)

History of administration of doxorubicin at >200 mg/m²

Lab requirements

Blood counts

absolute neutrophil count (anc) ≥1,500/μl, platelets ≥100,000/μl (or anc ≥500/μl and platelets ≥50,000/ μl in the presence of bone marrow involvement)

Kidney function

serum cr ≤2.0mg/dl or egfr ≥ 30ml/min according to the cockroft-gault formula

Liver function

alt ≤2.5x upper limit of normal (uln) (or ≤5x uln in the presence of liver involvement), total bilirubin ≤2x uln (or ≤3x uln in the presence of liver involvement)

Cardiac function

lvef ≥45% on echocardiography or muga

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify